Get started
Author

Andy H. Szeto

Observed names: A. Szeto, Andy Szeto, Szeto, Andy
ORCID: 0000-0002-9195-6520
Observed ORCID: 0000-0002-9195-6520
OpenAlex ID: A5048575614
Impact of High Volume Energy Drink Consumption on Electrocardiographic and Blood Pressure Parameters: A Randomized Trial
2019 · Sachin A. Shah, Andy H. Szeto, et al. · Journal of the American Heart Association · 126
Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA
2024 · Mazyar Shadman, Talha Munir, et al. · Journal of Clinical Oncology · 88
Pharmacokinetics and Pharmacodynamics of Apixaban in Nephrotic Syndrome: Findings From a Phase 1a Trial
2022 · Vimal K. Derebail, Jing Zhu, et al. · American Journal of Kidney Diseases · 20
PDF
P639: Zanubrutinib (zanu) Vs Bendamustine + Rituximab (br) in Patients (pts) With Treatment-naïve Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma (cll/sll): Extended Follow-up of the Sequoia Study
2023 · Talha Munir, Mazyar Shadman, et al. · HemaSphere · 18
ZANUBRUTINIB (ZANU) VERSUS BENDAMUSTINE + RITUXIMAB (BR) IN PATIENTS (PTS) WITH TREATMENT‐NAïVE (TN) CLL/SLL: EXTENDED FOLLOW‐UP OF THE SEQUOIA STUDY
2023 · M. Shadman, T. Munir, et al. · Hematological Oncology · 15
PDF
A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer
2021 · Stephanie I. Kim, Andy H. Szeto, et al. · PLoS ONE · 11
PDF
P662: Patient-reported Outcomes From a Phase 3 Randomized Study of Zanubrutinib Versus Bendamustine Plus Rituximab (br) in Patients With Treatment-naïve (tn) Cll/sll
2022 · P. Ghia, G. Barnes, et al. · HemaSphere · 6
Health-related quality-of-life in treatment-naive CLL/SLL patients treated with zanubrutinib versus bendamustine plus rituximab
2023 · Paolo Ghia, Gisoo Barnes, et al. · Current Medical Research and Opinion · 5
PDF
Zanubrutinib for the treatment of patients with del(17p) and/or TP53 CLL/SLL: analysis across clinical studies
2025 · Constantine S. Tam, Mary Ann Anderson, et al. · Blood Advances · 4
PDF
Correction: A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer
2021 · Stephanie I. Kim, Andy H. Szeto, et al. · PLoS ONE · 4
PDF
Sustained Superiority of Zanubrutinib vs Bendamustine + Rituximab in Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (TN CLL): 5-Year Follow-Up of Cohort 1 from the SEQUOIA Study
2024 · Mazyar Shadman, Talha Munir, et al. · Blood · 3
PDF
The feasibility and potential of pharmacogenetics to reduce adverse drug events in nursing home residents
2022 · Christine E. Kistler, Charles Adrian Austin, et al. · Journal of the American Geriatrics Society · 3
PDF
The Pharmacogenetics of Opiates and Its Impact on Delirium in Mechanically Ventilated Adults: A Pilot Study
2022 · C. Adrian Austin, Andy Szeto, et al. · Journal of Pharmacy Technology · 2
Response to Tyrosine Kinase Inhibitors in Real-World Patients With Chronic Myeloid Leukemia
2021 · Andy H. Szeto, Tyler Bucci, et al. · Annals of Pharmacotherapy · 2
Health-related quality of life in treatment-naive CLL/SLL patients treated with zanubrutinib versus bendamustine plus rituximab
2023 · Ghia, Paolo, Barnes, Gisoo, et al. · Figshare
Works count: 15
Citation count: 306
H-index: 6
I10-index: 6
Year
Topic
Type